NGNE insider transaction filings
Neurogene Inc. — 50 most recent Form 4 filings from SEC EDGAR, normalized by FilingPulse. Latest filing: 2026-07-07. Screen NGNE transaction legs live →
Insider transaction summary — last 90 days
2026-06-24 to 2026-09-22, from the filings listed below: 2 Form 4 filings. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): none reported.
- Open-market sales (code S, non-derivative): 5 legs across 2 filings by 1 insider — 9,600 shares, $339,962 total (shares × price as filed).
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 0.
- Largest priced transaction: sale of 4,200 shares @ $36.13 ($151,763) by Cvijic Christine Mikail, filed 2026-07-07.
By insider — same window
Open-market purchase/sale legs on non-derivative securities, grouped by the filing's reporting owner(s); joint filings appear once. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Insider | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|
| Cvijic Christine Mikail — President and CFO, Director | 2 | — | 5 legs · 9,600 sh · $339,962 | — |
Recent Form 4 filings — Neurogene Inc.
| Filed | Form | Insider | Reported transactions | Source |
|---|---|---|---|---|
| 2026-07-07 | 4 | Cvijic Christine Mikail — President and CFO, Director | Sale (S): 600 @ $36.02 · Sale (S): 4,200 @ $36.13 | EDGAR |
| 2026-07-02 | 4 | Cvijic Christine Mikail — President and CFO, Director | Sale (S): 739 @ $34.06 · Sale (S): 2,531 @ $34.58 · Sale (S): 1,530 @ $35.23 | EDGAR |
| 2026-06-16 | 4/A | Woods Keith — Director | Grant/award (A): 15,400 (derivative) @ $0 | EDGAR |
| 2026-06-16 | 4/A | Woods Keith — Director | Grant/award (A): 7,700 (derivative) @ $0 | EDGAR |
| 2026-06-16 | 4/A | Woods Keith — Director | Grant/award (A): 12,050 (derivative) @ $0 | EDGAR |
| 2026-05-08 | 4 | Cvijic Christine Mikail — President and CFO, Director | Sale (S): 4,800 @ $30.07 · Sale (S): 4,800 @ $32.44 | EDGAR |
| 2026-05-07 | 4 | Shafer Christina — Chief Commercial Officer | Grant/award (A): 120,000 (derivative) @ $0 | EDGAR |
| 2026-03-30 | 4 | Jordan Julie — Chief Medical Officer | Sale (S): 828 @ $21.89 | EDGAR |
| 2026-03-30 | 4 | McMinn Rachel — Chief Executive Officer, Director | Sale (S): 3,352 @ $22.07 | EDGAR |
| 2026-03-30 | 4 | Cvijic Christine Mikail — President and CFO | Sale (S): 2,558 @ $21.62 | EDGAR |
| 2026-03-17 | 4 | Cobb Stuart — Chief Scientific Officer | Sale (S): 3,991 @ $20.41 · Sale (S): 2,658 @ $21.34 · Sale (S): 148 @ $22.08 | EDGAR |
| 2026-03-17 | 4 | Cvijic Christine Mikail — President and CFO | Sale (S): 2,387 @ $20.42 · Sale (S): 1,395 @ $21.25 · Sale (S): 263 @ $22.02 | EDGAR |
| 2026-03-03 | 4 | Cvijic Christine Mikail — President and CFO | Sale (S): 4,800 @ $25.11 | EDGAR |
| 2026-02-24 | 4 | Woods Keith — Director | Grant/award (A): 12,050 (derivative) @ $0 | EDGAR |
| 2026-02-24 | 4 | Cobb Stuart — Chief Scientific Officer | Grant/award (A): 16,500 @ $0 | EDGAR |
| 2026-02-24 | 4 | Jordan Julie — Chief Medical Officer | Grant/award (A): 4,900 @ $0 · Grant/award (A): 29,600 (derivative) @ $0 | EDGAR |
| 2026-02-24 | 4 | Freedland Cory S. — Director | Grant/award (A): 12,050 (derivative) @ $0 | EDGAR |
| 2026-02-24 | 4 | Noonberg Sarah B. — Director | Grant/award (A): 12,050 (derivative) @ $0 | EDGAR |
| 2026-02-24 | 4 | PALEKAR ROHAN — Director | Grant/award (A): 12,050 (derivative) @ $0 | EDGAR |
| 2026-02-24 | 4 | McMinn Rachel — Chief Executive Officer, Director | Grant/award (A): 25,900 @ $0 · Grant/award (A): 155,100 (derivative) @ $0 | EDGAR |
| 2026-02-24 | 4 | Cvijic Christine Mikail — President and CFO | Grant/award (A): 22,000 @ $0 · Grant/award (A): 131,900 (derivative) @ $0 | EDGAR |
| 2026-02-24 | 4 | BAFFI ROBERT — Director | Grant/award (A): 12,050 (derivative) @ $0 | EDGAR |
| 2025-06-13 | 4 | Woods Robert Keith — Director | Grant/award (A): 12,050 (derivative) @ $0 | EDGAR |
| 2025-06-13 | 4 | PALEKAR ROHAN — Director | Grant/award (A): 12,050 (derivative) @ $0 | EDGAR |
| 2025-06-13 | 4 | Freedland Cory S. — Director | Grant/award (A): 12,050 (derivative) @ $0 | EDGAR |
| 2025-06-13 | 4 | Noonberg Sarah B. — Director | Grant/award (A): 12,050 (derivative) @ $0 | EDGAR |
| 2025-06-13 | 4 | BAFFI ROBERT — Director | Grant/award (A): 12,050 (derivative) @ $0 | EDGAR |
| 2025-05-15 | 4 | Cobb Stuart — Chief Scientific Officer | Sale (S): 6,797 @ $15.15 | EDGAR |
| 2025-03-28 | 4 | Cobb Stuart — Chief Scientific Officer | Grant/award (A): 7,200 @ $0 · Grant/award (A): 42,900 (derivative) @ $0 | EDGAR |
| 2025-03-28 | 4 | Cvijic Christine Mikail — President and CFO | Grant/award (A): 20,300 @ $0 · Grant/award (A): 122,000 (derivative) @ $0 | EDGAR |
| 2025-03-28 | 4 | Jordan Julie — Chief Medical Officer | Grant/award (A): 8,400 @ $0 · Grant/award (A): 50,300 (derivative) @ $0 | EDGAR |
| 2025-03-28 | 4 | McMinn Rachel — Chief Executive Officer, Director | Grant/award (A): 23,900 @ $0 · Grant/award (A): 143,500 (derivative) @ $0 | EDGAR |
| 2025-03-17 | 4 | Cvijic Christine Mikail — President and CFO | Sale (S): 4,501 @ $16.94 | EDGAR |
| 2024-11-27 | 4 | Samsara BioCapital GP, LLC — 10% owner Samsara BioCapital, L.P. — 10% owner AKKARAJU SRINIVAS — 10% owner | Purchase (P): 20,748 @ $24.91 · Purchase (P): 10,803 @ $26.01 · Purchase (P): 15,219 @ $26.73 · Purchase (P): 2,000 @ $27.50 | EDGAR |
| 2024-11-25 | 4 | Cvijic Christine Mikail — President and CFO | Purchase (P): 24,000 @ $20.48 | EDGAR |
| 2024-11-25 | 4 | McMinn Rachel — Chief Executive Officer, Director | Purchase (P): 47,500 @ $20.40 | EDGAR |
| 2024-06-17 | 4 | Woods Robert Keith — Director | Grant/award (A): 7,700 (derivative) @ $0 | EDGAR |
| 2024-06-17 | 4 | PALEKAR ROHAN — Director | Grant/award (A): 7,700 (derivative) @ $0 | EDGAR |
| 2024-06-17 | 4 | Noonberg Sarah B. — Director | Grant/award (A): 7,700 (derivative) @ $0 | EDGAR |
| 2024-06-17 | 4 | Freedland Cory S. — Director | Grant/award (A): 7,700 (derivative) @ $0 | EDGAR |
| 2024-06-17 | 4 | BAFFI ROBERT — Director | Grant/award (A): 7,700 (derivative) @ $0 | EDGAR |
| 2024-03-14 | 4 | McMinn Rachel — Chief Executive Officer, Director | Grant/award (A): 93,282 (derivative) @ $0 | EDGAR |
| 2024-03-14 | 4 | Cvijic Christine Mikail — President and CFO | Grant/award (A): 31,903 @ $0 · Grant/award (A): 53,900 (derivative) @ $0 | EDGAR |
| 2024-03-14 | 4 | Cobb Stuart — Chief Scientific Officer | Grant/award (A): 20,391 @ $0 · Grant/award (A): 34,450 (derivative) @ $0 | EDGAR |
| 2024-01-18 | 4 | Woods Robert Keith — Director | Grant/award (A): 15,400 (derivative) @ $0 | EDGAR |
| 2024-01-18 | 4 | PALEKAR ROHAN — Director | Grant/award (A): 15,400 (derivative) @ $0 | EDGAR |
| 2024-01-18 | 4 | Noonberg Sarah B. — Director | Grant/award (A): 15,400 (derivative) @ $0 | EDGAR |
| 2024-01-18 | 4 | Freedland Cory S. — Director | Grant/award (A): 15,400 (derivative) @ $0 | EDGAR |
| 2024-01-18 | 4 | Jordan Julie — Chief Medical Officer | Grant/award (A): 75,000 (derivative) @ $0 | EDGAR |
| 2024-01-18 | 4 | BAFFI ROBERT — Director | Grant/award (A): 15,400 (derivative) @ $0 | EDGAR |
Recent 8-K events — Neurogene Inc.
| Filed | Form | Items reported | Source |
|---|---|---|---|
| 2026-08-11 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-07-02 | 8-K | 1.01 — Entry into a Material Definitive Agreement 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-06-29 | 8-K | 7.01 — Regulation FD Disclosure 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-06-08 | 8-K | 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-06-04 | 8-K | 5.07 — Submission of Matters to a Vote of Security Holders | EDGAR |
| 2026-05-12 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-04-20 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-03-24 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-02-26 | 8-K | 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-01-12 | 8-K | 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?ticker=NGNE returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. API docs →